Assessment of the safety and efficacy of fondaparinux as an anticoagulant in haemofiltraion in patients with acute renal failure

This study is testing whether a blood-thinning medication called fondaparinux can safely be used to prevent blood clots from forming in the kidney replacement filter (haemofilter) in critically ill patients with acute kidney failure. When patients in the intensive care unit need continuous kidney replacement therapy (a form of dialysis for very sick patients), the filter can clog with blood clots. Researchers want to find out if fondaparinux keeps the filter working longer without causing unwanted bleeding. You may be eligible if: - You are an adult patient in the ICU who is expected to stay for more than 48 hours - You need continuous kidney replacement therapy (dialysis) - You or your next-of-kin is able to consent to the study You may NOT be eligible if: - You are pregnant - You have a pre-existing bleeding condition that prevents the use of blood thinners - You or your next-of-kin does not consent to participation Talk to your doctor about whether this trial might be right for you.